Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986218 With or Without Nivolumab and SBRT in Advanced Solid Malignancies
NCT04785287Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2021
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of BMS-986218 in solid tumor, sponsored by University of Texas MD Anderson Cancer Center. Started Mar 2021; status: terminated.
02
Drugs
BMS-986218
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04785287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04785287.